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ALZHEIMER’S-LIKE PATHOLOGY FEATURES IN BRAINS OF RABBITS 
WITH INFLAMED AORTIC ATHEROSCLEROTIC PLAQUES 
MATTHEW REY DIAMSE 
ABSTRACT 
 With the continual growth of the average age of the population and the global rise 
in obesity, it is important to investigate age related cognitive decline and its many related 
risk factors. Alzheimer’s Disease is the most common cause of dementia and has been 
linked to another inflammation-associated disease, atherosclerosis. In our lab’s recent 
findings, we have demonstrated this mechanistic link between inflammation and 
atherosclerosis with specialized pro-resolving mediators, such as lipoxin and resolvin 
found in Omega-3 fatty acids. Here we investigated the viability of our rabbit model of 
atherosclerosis as a model of Alzheimer’s Disease, in an effort to eventually test the 
impact of inflammation resolution as a treatment to AD. We developed and optimized an 
MRI protocol as a way to demonstrate and quantify the effect of vascular inflammation 
on a brain ex vivo in first a murine model of arterial stiffness. We then applied the refined 
protocol for use on our rabbit model of atherosclerosis. The mouse brains induced with 
arterial stiffness showed a significant increase of cerebral microbleeds (indicators of 
cerebral amyloid angiopathy). Some of the rabbit brains used for this study were found to 
be preserved for too long but found good images in recently harvested and perfused 
rabbit brains. While our findings are currently inconclusive, this thesis proposes a novel 
method for investigating the mechanistic and synergistic link between inflammation, 
atherosclerosis, and Alzheimer’s Disease.  
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1 
INTRODUCTION 
Alzheimer’s disease (AD) is the most common cause of dementia worldwide, 
accounting for 65-75% of all cases of dementia (Brookmeyer et al., 2011). It is 
characterized by neurodegenerative changes that are associated with early deficits in 
memory and has significant effects on the brain including changes in volume, structure, 
extracellular content, intracellular composition and synaptic connectivity. AD inexorably 
progresses to affect other cognitive domains and functions as well. The annual incidence 
of AD rises markedly with age, from 53 new cases per 1000 people aged 65 to 74, to 170 
new cases per 1000 people aged 75-84, and 230 new cases per 1000 people aged over 85 
(Alzheimers 2011). Similarly, its prevalence increases exponentially with age, in the 
United States rising from 2.32% in those aged 71-79 years to 29.60% in those aged over 
90 (Brookmeyer et al., 2011). The need to address this issue is urgent, especially since 
the average life expectancy of the world population has continued to trend upward. The 
number of people with dementia is projected to increase by 234%, from a currently 
estimated 24.3 million people to 81.1 million people by 2040 (Ferri et al., 2005). This is 
also accompanied with an increased vulnerability and susceptibility to other diseases 
(Zhaurova 2008). This presents immense health and economic challenges for both the 
present and the future.  
Pathology 
Numerous studies have characterized Alzheimer’s to three typical pathological 
features, the accumulation of beta-amyloid (Aβ) plaques, the formation of neurofibrillary 
 
 
 
 
2 
tangles composed of tau amyloid fibrils, and selective neuronal loss. Of these three, Aβ 
protein accumulation plays the most central role to the pathogenesis of AD. The Aβ 
protein is produced from the cleavage of the amyloid precursor protein. Mutations in this 
precursor protein can lead to an accelerated production of Aβ that, under disease 
conditions, cannot be cleared quickly enough resulting in its accumulation in the brain 
(Adlard et al., 2014). While the mechanism is not fully understood, the aggregation of Aβ 
may be caused by a number of factors including but not limited to, stable “misfolded” 
quaternary structures or consequence interactions with metals like zinc and copper which 
are dysregulated in the AD brain (Kawahara 2010). It is also unclear as to how Aβ 
accumulation is neurotoxic. There is evidence that suggests that oxidative stress and 
inflammation are among the chief pathways that Aβ act. Both of these factors have an 
established role in the biology of aging (Kawahara 2010).  
There are several ways in which oxidative stress is most likely driven by Aβ 
pathology in Alzheimer’s Disease. One mechanism is by dysregulation of important 
biological metals, such as calcium homeostasis through the disruption of mitochondrial 
membranes, creating calcium-permeable channels (Kawahara 2010). This can trigger 
apoptotic pathways of cellular death. Another mechanism is the impairment of the 
mitochondria that produces reactive oxygen species (ROS). ROS interacts with and alters 
cellular components, including nucleic acids, lipids, and proteins, causing damage to 
important cellular structures and reducing their functions (Adlard et al., 2014).  Usually, 
there are molecular mechanisms in place to minimize and repair oxidative damage, but 
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oxidative stress will occur when this function is overwhelmed (Adlard et al., 2014). It is 
then thought that Aβ -induced impairment to calcium homeostasis works in conjunction 
with oxidative stress to cause neuronal dysfunction and death (Adlard et al., 2014).  
These dying neurons then activate neuroinflammation, an early event in AD. 
Inflammatory mediators such as cytokines and activated complement components are 
elevated in vulnerable brain regions in AD, as discussed later.  
To summarize, these data support a primary role for Aβ in the pathogenesis of AD 
(although clearly there are other aspects that are also very important). As such, the ability 
to detect Aβ in the brain of living individuals has long been heralded as a key to allow the 
earliest detection of AD, with the subsequent benefit of expedited treatment and the hope 
of extending the number of disease-free years.  
Alzheimer’s Disease Imaging 
Recently, with advances in imaging technology, studies using MRI and PET 
neuroimaging of AD have identified a number of potential biomarkers, but have yet to 
gain acceptance as a diagnostic criteria clinically (Adlard et al., 2014). With this new 
development, there are now a number of quantitative structural MRI studies 
demonstrating volume loss in the medial temporal lobe, especially in the hippocampus, as 
a major and early marker of AD progression.  
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Figure 1. Progressive atrophy (medial temporal lobes) in an older cognitively normal 
(CN) subject, an amnestic mild cognitive impairment (aMCI) subject (seen as increased 
atrophy in medial temporal lobes), and an Alzheimer’s disease (AD) subject, which 
shows advanced degeneration of the brain (Adlard et al., 2014).   
Integral to this thesis, another of these biomarkers are cerebral microbleeds 
(MBs), which can be visualized both in vivo and ex vivo using specific magnetic 
resonance imaging sequences. MBs consist of deposits of blood degradation products that 
result from small chronic brain hemorrhages, mainly composed of hemosiderin, which is 
a strong paramagnetic material. Extensive research has demonstrated the value of MBs as 
markers of small-vessel disease and are thought to be representative of cerebral amyloid 
angiopathy (Ramirez et al., 2014). It is also important to note however, that MBs are also 
a common finding in healthy populations, much like amyloid-B aggregation.  
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Figure 2. Cerebral microbleeds as seen on magnetic resonance imaging gradient-recalled 
echo imaging (arrows). (A) Multiple lobar microbleeds distributed across the temporal 
lobes. (B) Isolated deep microbleed in the lateral aspect of the right thalamus (Ramirez et 
al., 2014). 
 
An important caveat is that even with these remarkable images, AD is unable to 
be definitively diagnosed until post-mortem examination and the reasons for neuronal 
death are not very clear. Also, when investigating amyloid plaque and cerebral 
microbleed progression in the earliest stages, they appear to correlate with subjective 
cognitive complaints, but not with objective measurements of memory and executive 
function (Amariglio et al., 2012). Despite these limitations, MRI is able to detect brain 
abnormalities associated with mild cognitive impairment and can be used to predict 
which patients with mild cognitive impairment may eventually develop AD. In later 
stages, MRI may show a decrease in the size of different areas of the brain (mainly 
affecting the temporal and parietal lobes). 
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There have also been observational studies that have discovered several 
modifiable risk factors for AD. According to a comprehensive systematic review of the 
evidence related to risk factors for cognitive decline and AD, the US National Institutes 
of Health highlighted diabetes mellitus, smoking, depression, mental inactivity, physical 
inactivity and poor diet as being associated with increased risk of cognitive decline, AD, 
or both (Daviglus et al., 2010). In further recent studies, an association was also 
demonstrated between the presence of vascular risk factors in mid-life and amyloid 
deposition later in life (Gottesman et al., 2017). This highlights the importance of 
understanding cardiovascular risk/function and lifestyle habits in regards to Alzheimer’s.  
Inflammation  
Considerable new research focus is on inflammation, which is the process by 
which the immune system recognizes and removes harmful stimuli and begins the healing 
process. There are two types of inflammation, acute and chronic. Chronic inflammation is 
a slow and long-term inflammation lasting for prolonged periods of several months to 
years. It is also characterized by infiltration at the tissue site by primary inflammatory 
cells such as macrophages, lymphocytes, and plasma cells, and the production of 
inflammatory cytokines, growth factors, and enzymes, thus contributing to the 
progression of tissue damage and secondary repair including fibrosis and granuloma 
formation (Pahwa, Jialal StatsPearls 2018). Research in Dr. Hamilton’s lab at BUMC has 
recently contributed strong evidence supporting the emerging broad view that chronic 
unresolved inflammation can impart systemic effects promoting or exacerbating 
 
 
 
 
7 
secondary conditions, including diabetes, rheumatoid arthritis, cancer, and Alzheimer’s 
disease. The potentially important mechanism linking atherosclerosis and Alzheimer’s 
disease is unclear and there is a need to identify the contribution of cardiovascular 
pathology to early cognitive decline and (vascular) dementia.  
Inflammation and Alzheimer’s Disease 
In older adults, chronic low-level inflammation is linked to cognitive decline and 
dementia (StatsPearls 2018). Mechanistic studies of the inflammatory factors and 
receptors mediating microglial localization and responses to Aβ have been fruitful for 
gaining insights into mechanisms. In vitro, Aβ has been shown to stimulate expression of 
nearly all the proinflammatory mediators (Lue and Walker 2001). Inflammation has also 
been identified to exacerbate the progression of AD pathogenesis. Pathologically 
vulnerable parts of the brain clearly show inflammation and inflammatory responses that 
include local upregulation of complement cytokines and other inflammatory mediators. 
In addition, AD affected brain neurons and neurites provide perfect stimuli for 
inflammation (Akiyama et al., 2000). Because of these findings, a study by Wang et al. 
investigated the claim that anti-inflammatory medications could defer or prevent the 
occurrence of Alzheimer’s Disease. Their observational studies led to the conclusion, that 
use of on-steroidal anti-inflammatory drugs (NSAIDs) was significantly associated with a 
reduced risk of AD compared to no use of NSAIDs, especially in long term users (Wang 
et al., 2015). This is illustrated in the proposed potential protective mechanisms of 
NSAIDs in AD (Figure 3). 
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Figure 3. Potential protective mechanisms of NSAIDs in AD (Weggen et al. 2007). 
Because of the long development time of Alzheimer’s in humans, it is important 
to utilize animal experimental models to discover associations and test therapeutics. 
Animal models of AD including cholesterol-fed and transgenic mice, cholesterol-fed and 
transgenic rabbits, aged dogs, and primates have all approximated one or more aspects of 
this disease and have done so in a relatively short period of time compared to human 
studies (Philipson et al., 2010).  
The overwhelming majority of AD research has been carried out in transgenic 
mouse models, which confer advantages in terms of time and cost-effectiveness. At the 
same time, they allow a detailed analysis of pathological mechanisms at molecular, 
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anatomical and cognitive/behavioral levels (Adlard et al., 2014). This animal model is 
able to show a variety of pathological biomarkers based on the type of transgenic mouse. 
 
 
Figure 4. (B) Five-way anatomic spatial coregistration of a 24-month-old APP/PS1 AD 
transgenic mouse brain. Ex vivo MRI scans of matched sections imaged using either a (A) 
T2SE or (D) T*2 GE pulse sequence. Matched adjacent histological sections processed 
with (G) DAB-enhanced iron staining, (J) thioflavine S amyloid staining, or (M) anti-Aβ 
peptide immunohistochemistry. Scale bar = 500 μm. (B,E,H,K,N) Higher magnification 
of hippocampal plaques positively matched by spatial coregistration. Corresponding 
plaques are labeled with numbers when present in a particular section. (C,F,I,L,O) Higher 
magnification of thalamic plaques positively matched by spatial coregistration. (O) Scale 
bar = 100 μm from Wengenack et al. (2011). 
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Though these mouse models have been used to investigate Aβ metabolism and 
amyloid deposition, they do not come without limitations. The detection of brain atrophy 
in transgenic mice has varied between structural MRI studies, and atrophic changes do 
not appear to correlate with the degree of Aβ deposition (Balducci and Forloni, 2011). 
Furthermore, the pattern and mechanisms of atrophy in mice appear to differ from those 
in human AD. 
Rabbits are another animal model, and cholesterol feeding for as little as eight 
weeks has produced as fourteen different indices of pathology that are similar to those 
seen in AD. These included intracellular and extracellular Aꞵ, breaches of the blood 
brain barrier, activation of microglia, apoptosis, increased levels of apolipoprotein E and 
phosphorylated tau protein (Woodruff-Pak 2008). Some studies have even tracked 
ventricular volume and related an increase in the ventricular volume to the hallmarks of 
AD, in addition to elevated Beta Amyloid counts. The rabbit animal model seems to be a 
better fit than a murine model for studying this type of systemic inflammatory disease. 
Furthermore, it has already been proven to be a robust model for another inflammatory 
disease, Atherosclerosis. 
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Figure 5. Panels show analysis of ventricular volume in a sample MRI axial scan for a 
rabbit that received chow and distilled water (A), chow and 0.24 ppm copper in distilled 
water (B), chow plus 2% cholesterol and distilled water (C), or chow with 2% cholesterol 
and 0.24 ppm copper in distilled water (D). The inset of each panel shows the third 
ventricle selected using the intensity-based threshold painting method. The white arrows 
indicate the barely detectable lateral ventricle (Deci et al., 2012).  
 
Inflammation and Atherosclerosis 
Atherosclerosis is an inflammatory disease that can cause or promote myocardial 
infarction, stroke, and ischemic gangrene. The atherosclerotic process begins with 
accumulation of cholesterol containing low-density lipoproteins accumulate in the intima 
which then activate the endothelium. Upon activation, there is an increase in interactions 
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with white blood cells, including leukocyte adhesion molecules and chemokines, which 
then promote recruitment of monocytes and T cells. These then differentiate into 
macrophages and upregulate scavenger and toll-like receptors, leading to foam-cell 
formation (Glass et al., 2001 and Hansson 2006). Damage to the endothelium causes T 
cells to recognize local antigens and help facilitate the T helper-1 response to secrete pro-
inflammatory cytokines that contribute to local inflammation and growth of the plaque 
(Hansson 2006).  
 
Figure 6. Chrostopher K.Glass, Joseph L.Witztum. Atherosclerosis: The Road Ahead. 
Cell. 2001; 104:503-516) 
 
Ongoing studies have shown that defective inflammation resolution, after the 
initial inflammatory response, is the cause of prevalent chronic inflammatory diseases, or 
in this case Atherosclerosis. This resolution is controlled by endogenous factors, 
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including fatty acid derived specialized proresolving mediators (SPMs) and proteins 
(Fredman, Tabas 2017). This imbalance between proresolving and proinflammatory 
mediators has been shown to be associated with prevalent diseases, including 
atherosclerosis, though the mechanisms are still largely unknown. Notably, this concept 
of dysregulated inflammation resolution in atherosclerosis has been known for several 
decades. The sections to follow will further detail work on therapeutic application of 
proresolving ligands in experimental atherosclerosis in animal models.  
These models are beneficial because currently, there is an inability to study 
atherosclerosis and sudden thrombosis in a controlled manner in humans (Phinikaridou 
2009). Specifically, the rabbit model, with pharmacological triggering at the end of the 
atherogenic diet, has been thoroughly evaluated as an animal model to study human 
systemic inflammatory diseases. A modified protocol of the Constantinides New Zealand 
white (CNZW) rabbit has been shown to be a robust model of human atherosclerosis and 
atherothrombosis, with similar plaque characteristics and progression. These rabbits 
develop foam-cell-rich (fatty streaks) plaques when short-term (6–10 weeks) cholesterol 
diets were the only stimulus used to induce atherosclerosis (Phinikaridou 2009). When 
coupled with arterial wall injury and hyperlipidemia, advanced lesions are formed 
producing human resembling atheroma in a short period of time (Abela GS 1995). 
Rabbits with these plaques are valuable for developing noninvasive imaging-diagnostic 
methods and testing dietary and pharmacological interventions (Phinikaridou 2009). 
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Figure 7. Histological classification of rabbit plaques based on the AHA criteria. A: 
Type II plaque. B: Higher magnification taken from the black box in A identifies foamy 
macrophages in the intima (arrow). C: Type III plaque. D: Higher magnification taken 
from the black box in C reveals foamy macrophages, foamy SMCs (arrow), and degraded 
tissue (*). E: Type IV plaque. F: Higher magnification taken from the black box in E 
shows a forming fibrous cap over a lipid core. The necrotic core is located deeper in the 
intima (Phinikaridou 2009). 
 
Treatment using SPM’s 
Dr. Hamilton’s lab, in collaboration with Forsyth Institute, demonstrated that 
treatment with SPM’s was able to decrease inflammation in the atherosclerotic aorta and 
a regression of other plaque features that promote plaque progression and thrombosis. 
The rabbit model therefore provides a possible method for treatment of other 
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inflammatory diseases that could be exacerbated by atherosclerosis. Previous 
collaborative studies done in the rabbit model between these labs have also shown a 
decrease in the pathological hallmarks of periodontitis as well as non-alcoholic fatty liver 
disease with the treatment of the SPM, resolvin (Hasturk et al. 2015, and Taylor et al 
2017).  
Specific Aims 
In this thesis, I present investigations into the pathological association between 
atherosclerosis and systemic inflammation, and brain damage in both a murine and rabbit 
model. Our hypothesis is that vascular inflammation directly contributes to the 
vulnerability of the brain to Alzheimer’s-like pathological features by increasing the 
amount of cerebral damage. To accomplish this aim, I refined and optimized MRI 
imaging methods for both an arterial stiffness murine model and an atherosclerosis rabbit 
model in an effort to show increased microbleed quantity in the brain ex vivo. Secondly, I 
present supportive histological evidence for the MRI images (which might not be 
completed at the time of writing this thesis).  
METHODS  
Mouse model of arterial stiffness 
The mice with vascular smooth muscle-specific Bcl11b deletion model was 
created as excerpted here from Dr. Francesca Seta unpublished methodology; 
“Floxed Bcl11b mice (Bcl11bflox/flox) in which Bcl11b’s exon 4, crucial for its zinc finger 
DNA binding activity, is flanked by loxP sites 8, were inter-crossed with transgenic mice 
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in which Cre-recombinase is linked to an estrogen receptor construct for tamoxifen-
inducible removal of Bcl11b (ER-Cre-Bcl11bflox/flox) and WT littermate controls. In 
order to study the functional role of Bcl11b in VSM cells, we bred Bcl11bflox/flox mice 
with transgenic mice in which Cre-recombinase expression is driven by smooth muscle 
myosin heavy chain 11 (SMMHC or MYH11) promoter 5 linked to an estrogen receptor 
construct (SMMHCCreERT2), which allows for tamoxifen-inducible removal of Bcl11b 
in vascular smooth muscle. Eight-week old ER-Cre-Bcl11bflox/flox or 
SMMHCCreERT2/Bcl11bflox/flox mice received tamoxifen (200µl, 2mg/d, 5 days) or 
vehicle (200µl, sunflower oil, 5 days) to obtain global Bcl11b null mice (BKO) and 
vascular smooth muscle specific Bcl11b-deficient mice (BSMKO) and WT littermate 
controls, respectively. In addition, to corroborate Bcl11b vascular effects in a second 
animal model, we inter-crossed Bcl11bflox/flox with transgenic mice in which Cre-
recombinase expression is driven by endogenous smooth muscle 22 α protein promoter 
(SM22α, transgelin; stock number 006878, The Jackson Laboratory) to generate mice with 
constitutive Bcl11b deletion in vascular smooth muscle (SM22αCre+ /Bcl11bflox/flox and 
SM22α-Cre- /Bcl11bflox/flox littermate controls). Mice were backcrossed into C57Bl/6J 
genetic background for at least 10 generations.” (Dr. Francesca Seta Unpublished data)  
This knockout procedure describes a whole-body knockout while the mice used were aorta 
specific. 
In this thesis, I included the brains of 6 Bcl11b KO (aorta specific) mice and 1 
wild type young control from our collaboration with Dr. Francesca Seta’s lab and 3 
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brains from age-matched wild type controls from our collaboration with Dr. Kathy 
Morgan’s lab. 6 training wild type mouse brains were also used for method development 
and testing.  
Rabbit model of atherosclerosis 
For this thesis I created 2 study groups comprised of a combination of two past 
rabbit studies in the Hamilton lab (using tissue that was perfused and preserved), and our 
current rabbit study involving in vivo laser imaging of a rabbit model of atherosclerosis. 
All male New Zealand white rabbits in this are adult aged (3 months old 2.8-3.0 kg), 
were purchased from Charles River Laboratories (Wilmingham, MA), and housed in the 
Boston University Medical Campus rabbit facility. Each rabbit was fed a normal chow 
and 1% Cholesterol (CHOL) containing diet (PharmaServe, Framingham, MA). Normal 
chow contained 16.5% protein, 41% carbohydrates, 22.5% fiber, 2% fat whereas the 
CHOL containing chow included 10,000 ppm cholesterol, 14.4% protein, 42.8% 
carbohydrates, 23.7% fiber, 2.4% fat by weight. The remaining mass consisted of 
moisture, ash, vitamins, and minerals. Animal chow was stored in a cool, dry location 
with refrigeration.  
For one study group (CHOL + injury; n=4), rabbits were placed on a three-month 
protocol with 1% cholesterol feeding. After two weeks of lipid diet, the rabbits were 
subjected to a well-established, published procedure to injure a region of the aorta to 
induce endothelial injury, which accelerates advanced plaque formation. Under general 
anesthesia (acepromazine [0.75 mg/kg], ketamine [35 mg/kg], and xylazine [2.5 mg/kg], 
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administered intramuscular), balloon injury of the abdominal aortic wall was performed 
using a 3F Fogarty catheter introduced through a right femoral artery cutdown. After the 
catheter was advanced to the diaphragm, the balloon was inflated and the catheter was 
gently retracted toward the iliofemoral artery. This was repeated three times 
(Phinikaridou 2009).  After two months, these rabbits were placed on normal diet (Figure 
8). 
 
Figure 8. 1% Cholesterol Diet Timeline 
For the second study group (CHOL + injury + RvE1 treatment; n=2), the protocol 
was the same but with the addition of oral therapy at the time of normal diet for 4 weeks. 
To test whether atherosclerosis could be reduced by therapy, 8 μg LXA4 was applied by 
topical swab 3 times per week (last 2 weeks not shown in Figure 10). Control rabbits 
(normal diet; n=3) were fed normal chow (LabDiet, Saint Louis, MO). 
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Figure 9. 1% Cholesterol Diet + Treatment Timeline 
Plaque Triggering with Russell’s Viper Venom (RVV) 
At the end of the 12 weeks of preparatory period, plaques were tested for 
vulnerability to disrupt (thrombose) by pharmacologically “triggering” with 
intraperitoneal injection of Russell's viper venom (0.15 mg/kg; Enzyme Research, South 
Bend, IN) followed 30 min later by intravenous injection of histamine (0.02 mg/kg; 
Sigma-Aldrich, St. Louis, MO) (Phinikaridou 2009). This procedure was performed twice 
within 48 h on two consecutive days (at 1PM of each day). Russell's viper venom is a 
procoagulant factor and endothelial toxin, and histamine acts as a vasopressor in rabbits. 
Heparin (1,000 USP units; Sigma-Aldrich) was administered intravenously prior to 
euthanasia to prevent postmortem blood clotting. (Phinikaridou 2009). 
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Rabbit and mouse brain perfusion 
Two Stage Perfusion for Fresh and Fixed Tissue Harvest: In order to harvest 
tissue for biochemical studies and to obtain well-fixed tissue for light microscopic 
histology and immunocytochemistry from the same animal, we developed a two-stage 
perfusion procedure. This method begins with the perfusion of 2 liters of Kreb’s buffer at 
4°C and is followed immediately by soaking in 8 liters of 4% paraformaldehyde at 37°C. 
Fresh, unfixed samples are collected during the Kreb’s infusion prior to fixative. The 
perfusion is then switched to 4% paraformaldehyde about 3 to 4 minutes after the flow of 
Krebs was started. The paraformaldehyde is allowed to flow until finished, normally 
about 10 minutes. The use of 2 liters of ice-cold Krebs flushes the blood from the brain 
while cooling it to retard anoxia induced proteolysis, while the 4 liters of warm 4% 
Paraformaldehyde is sufficient to produce rapid and optimal fixation of the remainder of 
the brain. 
Magnetic Resonance Imaging of Cerebral Microbleeds 
A High field MRI (11.7T; Bruker Biospin Corporation, Billerica, MA) was used 
to study excised brains rinsed in cold saline, fixed in 10% neutral buffered formalin, and 
then placed in MR-signal inert fomblin oil (Sigma Aldrich). The fomblin oil suppresses 
background signal, providing high signal-to-noise proportion during visualization of the 
tissue (Taylor et al.). To reduce the number of artifacts produced by air bubbles, each 
sample was placed under vacuum for 30 minutes in fomblin oil. Our MRI protocol 
consisted of standard image sequences: T1W, T2W, and T2*. After these initial images 
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were acquired, a contrast enhancing agent was added to provide an even greater signal-to-
noise ratio in brain, and to enhance detection of cerebral microbleeds. We tested two 
contrast agents in this study, McCl2 and gadolinium (Gd) which we added to saline in 
different concentrations that are described in Table 1. The brains were soaked for 5 days 
to allow the stain to be absorbed into the brain. The MRI protocol was once again 
conducted and results were compared both between pre- and post-enhancement for each 
contrast agent. Cerebral microbleeds were measured quantitatively using a few criteria 
for MB identification: 1) black on the T2*-weighted MRI, 2) round or ovoid (rather than 
linear), 3) Surrounded by brain tissue that is not deteriorated/damaged in the 
preservation/perfusion process, 4) Distinct from blood vessels that run through the brain. 
To quantify, I manually counted any microbleeds that followed the above criteria, in 3 
distinct section of the brain; cortex, hippocampus/striatum, and thalamus.  
Table 1 
Contrast Agents Used Concentration in Saline 
Gadolinium  1:100 
MnCl2 1x  1:100 
MnCl2 5x 5:100 
MnCl2 10x 1:10 
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Histology 
After MRI, mouse brains were equilibrated in 30% sucrose solution to protect 
them from cracking and crumbling during cryo-sectioning. Using a Leica Cryostat 
machine, the mouse brains were cut into 30-micron slices and placed on slides. To 
increase efficiency in this process, especially for brains with very few microbleeds, the 
MRI data was used to pinpoint the location of the microbleeds to provide a marker to 
begin slicing. These were then stored in -20℃ until staining. Prussian blue stain was used 
to show microbleeds by detection of hemosiderin, a marker of sub-acute 
microhemorrhage.  
After MRI, rabbit brains were also equilibrated in 30% sucrose solution, flash 
frozen in liquid nitrogen, and stored in -80℃ until cryo-sectioning. A mechanical 
microtome was used instead in order to fit the larger sized brain of the. 40-micron slices 
of rabbit brain were collected in series and then frozen for future staining and 
immunohistochemistry. 
Statistical Analysis 
 Statistical comparison was carried out on data derived from Bcl11b knockouts, 
age-matched wild type controls, or young wild type control mouse groups. Two-sample 
Student’s t-test for the mean difference per mouse group and mouse brain region was 
carried out in Excel (Microsoft Corporation, Redmond, WA).  
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RESULTS 
MRI Method Development 
 Our new images of brains had an exceptional high resolution which is in part 
because we have previously worked with gadolinium contrast. Consistent with previous 
studies, my initial studies showed that gadolinium does not stain homogeneously, making 
the brain easily differentiated. This is caused by the differential binding of the contrast 
agent in the brain tissue. The MnCl2 contrast agent did produce images with a better 
signal-to-noise ratio compared to images without any staining, but the improvement was 
not dramatic. Without staining, we observed a minimal amount of microbleeds that fit the 
established criteria although the noise from the brain image makes quantification very 
difficult. Using MnCl2 as the contrast agent, more microbleeds were revealed but much 
less so than Gd. Increasing the concentration of MnCl2 to either a 5x concentration 
increased the signal-to-noise ratio slightly and was used for the remainder of the MnCl2 
tests. At higher concentrations, such as 10x and higher, there was a decrease in signal-to-
noise ratio. An increase in image resolution, unfortunately also made it also easier to 
misclassify microbleeds for other physiological (blood vessels and iron pockets) or non-
physiological (perfusion/fixation damage) features. Interestingly, there were a few 
instances where a definitive microbleeds can be found on the Mn stained brain image but 
not on the Gd. This opens the possibility that Gd is the optimal contrast agent to locate 
and define cerebral microbleeds in this animal model ex vivo. In any case, since Gd 
provided the clearest and most easily determined images, our lab considered the image 
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analysis to be good to excellent, and it was used as the contrast agent for the remainder of 
the study.  
 
Figure 10. Testing Magnevist Gadolinium (Gd) contrast and MnCl2 in mouse brains with 
MRI. Asterisks show probable places of cerebral microbleeds. Gd staining provides a 
much clearer image, with distinctions between brain regions.  
Mouse Brain Analysis   
 The brains from the Bc11b knockout mice for a model of arterial stiffness were 
analyzed and compared with age-matched control and young control mice stained with 
Gd to give unique data for MRI detection of brain microbleeds. They were kindly 
provided by Dr. Francesca Seta’s lab. We found that among young controls (3 to 8-
month-old) there were very little to no microbleeds found in any of the 3 regions of the 
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brain; cortex, hippocampus, and thalamus. With the 19-month age-matched controls from 
archived mouse data obtained in our lab, we observed microbleeds in mainly the 
thalamus region of the brain. However, these images were of lower resolution and a 
proper analysis was difficult to obtain. The Bc11b knockout mice (17-month) had the 
greatest quantity of microbleeds, and were found in greater quantity in both the 
hippocampus and the cortex.  
Table 2. Mouse brains scanned using MRI protocol 
Brain # Age (months) Mouse Type Stain 
1 7 Wild Type 1x MnCl2 
2 8 Wild Type Gd 
3 8 Wild Type None 
4 8 Wild Type Gd 
5 8 Wild Type 5x MnCl2 
6 3 Wild Type Gd 
7 3 Angiotensin II treated, WT Gd 
8 3 Angiotensin II treated, WT 5x MnCl2 
9 ? High Fat High Sucrose Gd 
10 3 Wild Type 5x MnCl2 
11 3 Wild Type 5x MnCl2 
12 3 Wild Type Gd 
13 3 Wild Type Gd 
14 17 Bcl11b Knockout Gd 
15 17 Bcl11b Knockout Gd 
16 17 Bcl11b Knockout Gd 
17 17 Bcl11b Knockout Gd 
18 17 Bcl11b Knockout 5x MnCl2 
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19 17 Bcl11b Knockout Gd 
 
 
Figure 11. Side-by-side comparison of a young control (left), 19-month age-matched 
control (middle), and an 18 month Bcl11b KO mouse (right). A noticeable increase in 
damage (microbleeds) in the thalamus region of the brain is demonstrated. 
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Figure 12. The increase in hippocampal microbleeds in an arterial stiffness mouse model 
is significantly greater than in an age-matched control p = 0.003. While not significant, 
p=0.083, there appeared to be an increase in microbleeds in the cortex in the arterial 
stiffness mouse model. Interestingly, the increased number of microbleeds in the 
thalamus region of these KO mice had no significant differences with their age-matched 
controls. We stipulate that the Bcl11b KO mice develop microbleeds in more varied parts 
of the brain, in contrast to what we believe are physiological features of aging in the 
thalamus region of the mouse. Young control mice had no discernable microbleeds, using 
the same quantifying criteria. 
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Table 3. Quantification of Microbleeds Across 3 Regions of the Brain 
Project 
Mouse 
# Cortex Hippocampus Thalamus 
KO      
Seta 14 1 4 8 
Seta 15 2 2 5 
Seta 16 0 3 15 
Seta 17 3 4 5 
Seta 19 2 2 3 
Age-Matched 
Control     
Archive 
(Morgan) 8 1 1 10 
Archive 
(Morgan) 9 0 0 5 
Archive 
(Morgan) 10 0 0 4 
Young Control      
Seta 2 0 0 0 
Seta 6 0 0 0 
 
Rabbit Brain Analysis 
 Rabbit brains were imaged using the same MRI protocol developed and refined in 
the mouse model. Our lab’s preserved rabbit brains were used as training samples for 
testing.  
Table 4. Rabbit Study Groups 
Rabbit # Study Group Year of Study Rabbit Brain Status 
Control    
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BY1 Normal Diet  Current Alive 
BY2 Normal Diet + Injury Current Performed Histology 
4C Normal Diet 2015 Imaged 
Experimental    
5A1 CHOL + Injury Current RVV triggered, Alive 
5A2 CHOL + Injury Current In PBS Solution 
5A3 CHOL + Injury Current RVV triggered, Alive 
3A CHOL + Injury 2012 Imaged 
Treatment    
4R1 CHOL + Injury + RvE1 2015 Imaged 
4R2 CHOL + Injury + RvE1 2015 Deteriorated 
 
 Rabbit brains were challenging to image and analyze because it was difficult to 
determine whether the damage in the brain was due to imperfect preservation techniques 
done on our past rabbits or the incidence of atherosclerosis. Past data therefore was 
unreliable and I was not able to quantify the cerebral microbleeds in the rabbit as in the 
mouse. Using rabbits in a current ongoing study in our lab, I was able to produce high 
resolution images which would be ideal in identifying MBs. However, there are only a 
small number of rabbits in this study (n=5) and was unable to obtain the brain tissue till 
the completion of the rabbit protocol. I completed imaging in 1 control rabbit from this 
study so far. In these current rabbits, we will continue to follow the perfusion protocol 
provided by Dr. Farzad Mortazavi, Assistant Professor of Neurobiology, at BUMC.  
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Figure 13. Select axial slices of Gd stained rabbit brains using T2* MRI sequence. It 
is important to identify the different states of preservation and perfusion for each of these 
ex vivo samples. BY2 is the only brain in this figure that underwent the perfusion method 
used in this thesis. It is possible that Gd uptake into old samples is not as well 
differentiated as in fresh samples. There is a drastic difference in resolution and contrast 
in the BY2 rabbit brain when compared to the rabbit brains from past studies. Upon 
observation, no significant differences can be found between these brains. While there are 
some examples of microbleeds that fall under the designated criteria, I am unable to 
determine at this time whether it is because of the different perfusion techniques used or 
because of the atherosclerosis induced in the rabbit.   
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DISCUSSION 
 
 The focus of this thesis was to investigate the association between systemic 
inflammation and brain damage in two animal models. To do this, we first developed an 
imaging protocol in an arterial stiffness murine model, then applied this protocol to our 
existing atherosclerosis rabbit model.  
As shown by our ex vivo MRI, mice with increased arterial stiffness due to the 
Bcl11b knockout showed increased cerebral microbleed quantity when compared to an 
age-matched control mouse. That the arterial stiffness could contribute to both the 
increased production of MBs and the spread of MB occurrence to other regions of the 
brain, the cortex and hippocampus. Because we found similar counts of MBs in the 
thalamus between the knockout mice and the age-matched controls, we assumed that the 
MBs in this brain region were mainly due to physiological aging. We therefore confirmed 
that this mouse model is capable of developing quantifiable cerebral microbleeds and 
support the hypothesis that systemic inflammation exasperates brain damage and 
pathology.  
These findings also support the use of MRI technology as a means to identify 
pathological features of AD in vivo and could with further studies potentially predict the 
likelihood and severity of AD progression. Currently, our lab is collaborating to further 
investigate the mechanism linking inflammation and arterial stiffness in the Bcl11b mice, 
testing for inflammatory biomarkers to hopefully identify the inflammatory role. This 
will be done by analyzing the blood of these knockout mice, and matching up the 
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histological slices of the brains to the MRI images. Ideally, we would like to see that the 
microbleeds identified in our images correlate with the Prussian blue staining in 
histology.  
 In the rabbit model, my studies were less successful in identifying any 
association. Because of the different perfusion methods used on the rabbits used in this 
thesis, it is difficult to determine whether rabbits produce cerebral microbleeds at all. 
Preservation was a key issue in these brains. Specifically, the 4R2 brain could not be 
imaged because the cortex region was deteriorated after storage, and the entire brain 
broke into pieces as I transferred it into a fomblin filled tube. Most of the previously 
preserved brains were easily shredded even with careful use of forceps. We did find 
however a significant difference in signal-to-noise ratio between the old rabbit samples 
and the one control rabbit brain that was imaged, BY2. For future studies, I will continue 
to use this MRI and perfusion protocol on the remaining brains once the tissue is finally 
harvested and our MRI machine is fully repaired. No definitive microbleeds were found 
in any of the images taken for this thesis, but the pivotal rabbit brains (5A1, 5A2, 5A3) 
have yet to be perfused and imaged. Our past rabbit brain samples were probably 
preserved for too long, and fresh tissue is needed to get a clear image of cerebral 
microbleeds in this rabbit model.  
Histology provides other indices to identify AD pathological features. 
Unfortunately, in the two brains that I attempted to cryo-section (3A and BY2), both 
shattered during slicing. A benefit of this work is that certain issues pertaining to the 
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cryo-protection of the brain were identified: one was that the brain was not fully 
equilibrated in the 30% sucrose solution, and another was possibly related to how fast the 
brain needs to be frozen in order to start slicing. In the current methodology, we use 
liquid nitrogen to flash freeze the brain by dipping the entire brain into the liquid. In 
future experiments, we will try using dry ice for a slower freezing process. Optimizing 
our cryo-sectioning section of our protocol, histology will facilitate investigation of the 
fourteen other indices of pathology in rabbits that are similar to those seen in AD. These 
include intracellular and extracellular Aβ, breaches of the blood brain barrier, activation 
of microglia, apoptosis, increased levels of Apolipoprotein E, phosphorylated tau protein 
and neurovascular changes. Depending on the results of histology, it would provide a 
pipeline to investigating treatment mechanisms of AD using SPMs such as resolvin, 
similar to our rabbit model of atherosclerosis. 
While the results may currently be inconclusive, this thesis proposes a novel 
method for studying AD in both a murine and rabbit model. In a mouse model, AD like 
features in an MRI image appear to be exacerbated when both arterial stiffness and 
inflammation is induced through the Bcl11b knockout, whereby there is a significant 
increase in the number of microbleeds in brain regions not correlated to physiological 
aging. While our rabbit model is a fantastic model for atherosclerosis, this study has yet 
verified it as a proper model for Alzheimer’s Disease. However, these findings provide a 
basis for detailed investigation of the mechanisms of inflammation. In the future, I hope 
to assess the impact of pro-resolving mediators of inflammation, including resolvins and 
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lipoxins, molecules that have been shown to be successful in the possible prevention of 
inflammation-associated disease.  
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